Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two programs for the self-assessment of patients with generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). These severe chronic diseases are difficult to monitor as there is currently no objective measurement tool to track symptom progression over time. Digital biomarkers could provide data to improve remote monitoring of disease symptoms and enhance communication between patients and healthcare professionals. These programs are supported by Alexion, AstraZeneca Rare Disease, and selected digital biomarkers will be validated in multicenter comparative studies against clinical standards.